concentration defect, an almost invariable feature of nephrocalcinosis,2 So any rise of urine erythropoietin concentration probably represented a true increase in erythropoietin excretion.
The results are shown in the table. Five of the six patients studied had a decreased plasma volume. Four of six patients studied had a definitely raised red cell mass, and one a marginally raised red cell mass. One other patient had significantly increased red cell production despite a blood haemoglobin concentration of 18 2 g/dl and haematocrit value of 57 %'. Thus, of seven patients studied, five had true erythrocytosis, one marginal erythrocytosis, and one pseudoerythrocytosis. In the three patients studied whole blood viscosity was above the upper limit of normal. Platelet and white cell counts were normal in all patients.
Urine erythropoietin concentration was raised in three of the four patients studied with erythrocytosis, and the normal value in patient 9 may be inappropriately high for someone with a haemoglobin concentration of 18 2 g/dl. Urinary erythropoietin concentration measured in 11 other patients with nephrocalcinosis (four with renal tubular acidosis, seven with medullary sponge kidney) was considerably raised in five, mildly raised in four, and normal in two.
Comment
Erythropoietin is a glycoprotein of molecular weight 36 000,3 and, like small-molecular-weight proteins, is probably filtered by the renal glomerulus and reabsorbed by the proximal tubule. The increased urinary erythropoietin in these patients is unlikely to have been due to tubular damage, as they have no evidence of abnormal tubular handling of amino-acids, glucose, or '5,-microglobulin. Thus the increased erythropoietin excretion of these patients is probably secondary to increased erythropoietin production, possibly stimulated by localised tissue hypoxia4 related to areas of nephrocalcinosis.
The importance of erythrocytosis in these patients is difficult to assess. Patients with nephrocalcinosis almost invariably have urine concentration defects2 and often have salt-losing nephropathy, and are therefore likely to have a low plasma volume and be at particular risk of developing hyperviscosity and thrombotic complications.5 The aim of treatment must be to reduce the haematocrit value and whole blood viscosity, and sodium supplements may be useful in an attempt to increase plasma volume. Careful follow-up is indicated and, should thrombotic episodes occur, then venesection using the haematocrit value and whole blood viscosity as guides to treatment should be started. When red cell production is being driven by an inappropriately high erythropoietin production the use of 32p may be justified. Patient No 7 was treated with 32p and venesection and survived another 20 years before dying of his third myocardial infarct.
Thus medullary nephrocalcinosis, from whatever cause, should be added to the list of causes of renal erythrocytosis, the increase in blood haemoglobin concentration being due to a combination of diminished plasma volume and the increased red cell mass due to raised production of erythropoietin. 
